CTOs on the Move

Provivi

www.provivi.com

 
We are a groundbreaking science-based company creating scalable, safer insect control technology that will improve the quality of life for all humans and our world.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.provivi.com
  • 1701 Colorado Ave
    Santa Monica, CA USA 90404
  • Phone: 310.828.2307

Executives

Name Title Contact Details

Funding

Provivi raised $21M on 11/29/2017
Provivi raised $85M on 10/15/2019
Provivi raised $10M on 02/24/2021

Similar Companies

Biotix Holdings

Biotix Holdings is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioworld

Bioworld is a Dublin, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Onconano Medicine

OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.

AES OPTICS

AES OPTICS is a Senatobia, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spero Therapeutics

Spero is a multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to identifying, developing and commercializing novel treatments focused on unmet needs of patients with multidrug-resistant (MDR) bacterial infections. Spero`s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero`s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial infection.